New Therapeutic Options in Mild Moderate COVID-19 Outpatients

Abstract

Background: In recent years, the therapeutic options for COVID have significantly improved; however, the therapies are expensive with restricted access to drugs, and expeditious and difficult to manage at home. We investigated the effect of pidotimod in preventing hospitalization in patients with mild-moderate COVID-19. Methods: A total of 1231 patients between January and June 2021 were screened. A total of 184 patients with mild-moderate COVID-19 were enrolled and divided into two groups: group-A (97) had undergone therapy with pidotimod 800 mg bid for 7–10 days and group-B (87) had other therapies. We excluded those who had undergone complete vaccination course, monoclonal anti-spike/antivirals or the co-administration of pidotimod-steroid. The primary outcome chosen was the emergency room, hospitalization, and deaths for COVID-related causes; the secondary outcome chosen was the duration of COVID-19 illness. Results: A total of 34 patients (18.5%) required hospital treatment, 11 in group-A and 23 in group-B (11.3% vs. 26.4%, p = 0.008). The median disease duration in group-A was 21 days (IQR 17–27) vs. 23 (IQR 20–31) in group-B (p = 0.005). Patients in the pidotimod group had higher SpO2 in the walking test (IQR 96–99% vs. IQR 93–98%, p = 0.01) and a lower need for steroid rescue therapy (11.5% vs. 60.9%, p < 0.001). Conclusions: In the first phase of disease, pidotimod can represent an effective, low-cost, weapon, without restrictions of use, that is able to prevent a second aggressive phase and promote faster virological recovery.

Are monoclonal antibodies effective in patients with severe obesity in SARS‐CoV‐2 infected?

“…But in our study, despite the timing of administration, the efficacy of the therapy was confirmed in obese and nonobese patients. This finding could be explained by the administration of home therapy with pidotimod and cholecalciferol 13 …”

“…This finding could be explained by the administration of home therapy with pidotimod and cholecalciferol. 13 …”

“…This finding could be explained by the administration of home therapy with pidotimod and cholecalciferol. 13 The immunomodulant Pidotimod and cholecalciferol may improve the immune system response against SARS-CoV-2. 10 Pidotimod decreases IL-6 production, while cholecalciferol can regulate immune function during COVID-19.…”

Immunoglobulin A as a Key Immunological Molecular Signature of Post-COVID-19 Conditions

“…Previous studies have reported high IgA production in the acute phase of COVID-19 and a marked decrease in IgA in the following months [ 36 , 37 ]. Because of this, drug therapies have been developed to modulate and enhance IgA production to treat SARS-CoV-2 infection [ 38 , 39 ]. On the other hand, we have previously observed IgA production for a prolonged period of at least 2 months after infection with SARS-CoV-2, but no correlation with PCC was investigated in this case [ 20 ].…”

Antimicrobial resistance in intensive care patients hospitalized with SEPSIS: a comparison between the COVID-19 pandemic and pre-pandemic era

“…It has had a dramatic effect on the world, causing almost 7 million deaths worldwide and changing daily life. COVID-19 has many reports concerning different clinical manifestations and different risk factors and biomarkers associated with the worsening (1)(2)(3). According to a report from the end of May 2020, 1.3 million cases were reported to the United States Centers for Disease Control and Prevention (CDC), with 14% requiring hospitalization, 2% admitted to the intensive care unit (ICU), and 5% dying.…”